Department of Dermatology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, Fukuoka 807-8555, Japan.
Int J Mol Sci. 2022 Jan 20;23(3):1119. doi: 10.3390/ijms23031119.
Malignant melanoma is one of the representative skin cancers with unfavorable clinical behavior. Immunotherapy is currently used for the treatment, and it dramatically improves clinical outcomes in patients with advanced malignant melanoma. On the other hand, not all these patients can obtain therapeutic efficacy. To overcome this limitation of current immunotherapy, epigenetic modification is a highlighted issue for clinicians. Epigenetic modification is involved in various physiological and pathological conditions in the skin. Recent studies identified that skin cancer, especially malignant melanoma, has advantages in tumor development, indicating that epigenetic manipulation for regulation of gene expression in the tumor can be expected to result in additional therapeutic efficacy during immunotherapy. In this review, we focus on the detailed molecular mechanism of epigenetic modification in immunotherapy, especially anti-PD-1/PD-L1 antibody treatment for malignant melanoma.
恶性黑色素瘤是具有不良临床行为的代表性皮肤癌之一。目前采用免疫疗法进行治疗，可显著改善晚期恶性黑色素瘤患者的临床结局。另一方面，并非所有这些患者都能获得治疗效果。为了克服当前免疫疗法的这一局限性，表观遗传修饰是临床医生关注的一个重点问题。表观遗传修饰涉及皮肤的各种生理和病理状况。最近的研究表明，皮肤癌，特别是恶性黑色素瘤，在肿瘤发展方面具有优势，表明对肿瘤中基因表达的表观遗传调控可以预期在免疫治疗期间产生额外的治疗效果。在这篇综述中，我们重点介绍了表观遗传修饰在免疫治疗中的详细分子机制，特别是抗 PD-1/PD-L1 抗体治疗恶性黑色素瘤。
